The partnership comes as the country is dealing with a shortage of the emergency allergy therapies – a number of epinephrine auto-injector manufacturers have reported supply issues to the FDA.
In August, Kaleo confirmed that despite ongoing manufacturing delays detailed by other manufacturers, Kaleo’s Auvi-Q device is available via prescription and that the privately-held company has ‘sufficient supply to meet any anticipated demand.’
“The health and well-being of our customers is of the upmost importance,” Richard Ashworth, Walgreens’ president of operations, said in prepared remarks. “Walgreens pharmacists continue to care for and work with patients and their prescribers to ensure they have access to the epinephrine auto-injectors they need, and we’re pleased to work with kaléo to help meet the demand for epinephrine auto-injectors across the country.”
“Thanks to this collaboration with Walgreens, any patient who is having difficulty filling a prescription for an epinephrine auto-injector now has the opportunity to get Auvi-Q through Walgreens,” Phil Rackliffe, GM of Kaleo’s allergy & pediatrics unit, added. “We are working with insurance providers to maximize coverage of Auvi-Q for as many patients as possible.”